Literature DB >> 11194792

Epidemiology of meningitis and bacteraemia due to Streptococcus pneumoniae in The Netherlands.

L Spanjaard1, A van der Ende, H Rümke, J Dankert, L van Alphen.   

Abstract

In The Netherlands, accurate data on the epidemiology of pneumococcal meningitis are available through a clinical microbiology laboratory-based national surveillance of cerebrospinal fluid isolates. The Netherlands Reference Laboratory for Bacterial Meningitis receives isolates of about 80% of all meningitis cases and about 40% of bacteraemic cases. The incidence of pneumococcal meningitis has increased slowly from 1.0/100,000 in 1990 to 1.5/100,000 since 1996. The highest age-specific incidence of meningitis was observed in children < 5 y of age (8.2/100,000 in 1999). Of all isolates, 35% were from children < 5 y of age. The number of isolates from non-meningitis patients with bacteraemia increased considerably since the early 1990s, especially among the elderly. The highest incidence was found in 1996, probably owing to a relatively severe winter. During 1995-1999, pneumococcal meningitis in The Netherlands was caused mainly by serotypes 3, 6B, 7F, 9V, 14, 18C, 19F, and 23F. Of the cases in children < 15 y, almost half were caused by serotypes 6B, 14, 18C, and 19F. The serotypes present in the 23-valent polysaccharide and 7-valent conjugate vaccines accounted for 87% and 47% of all meningitis cases, respectively. Pneumococcal resistance to penicillin in The Netherlands is still low, at about 1%. Genotypically, resistant strains belong to many clones. Horizontal transfer of capsular genes occurs among these isolates. In The Netherlands, 45% of cases of pneumococcal meningitis have severe predisposing factors. The case-fatality rate was significantly higher among patients with impaired immunity than among those with a break in the integrity of the dura.

Entities:  

Mesh:

Year:  2000        PMID: 11194792     DOI: 10.1111/j.1651-2227.2000.tb00778.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  5 in total

1.  Burden of paediatric invasive pneumococcal disease in Europe, 2005.

Authors:  E D G McIntosh; B Fritzell; M A Fletcher
Journal:  Epidemiol Infect       Date:  2006-09-07       Impact factor: 2.451

Review 2.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  The development of a 16S rRNA gene based PCR for the identification of Streptococcus pneumoniae and comparison with four other species specific PCR assays.

Authors:  Nabil Abdullah El Aila; Stefan Emler; Tarja Kaijalainen; Thierry De Baere; Bart Saerens; Elife Alkan; Pieter Deschaght; Rita Verhelst; Mario Vaneechoutte
Journal:  BMC Infect Dis       Date:  2010-04-29       Impact factor: 3.090

4.  Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002.

Authors:  Kimiko Ubukata; Naoko Chiba; Keiko Hasegawa; Reiko Kobayashi; Satoshi Iwata; Keisuke Sunakawa
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

5.  Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination.

Authors:  Germaine Hanquet; Pavla Krizova; Palle Valentiner-Branth; Shamez N Ladhani; J Pekka Nuorti; Agnes Lepoutre; Jolita Mereckiene; Mirjam Knol; Brita A Winje; Pilar Ciruela; Maria Ordobas; Marcela Guevara; Eisin McDonald; Eva Morfeldt; Jana Kozakova; Hans-Christian Slotved; Norman K Fry; Hanna Rinta-Kokko; Emmanuelle Varon; Mary Corcoran; Arie van der Ende; Didrik F Vestrheim; Carmen Munoz-Almagro; Pello Latasa; Jesus Castilla; Andrew Smith; Birgitta Henriques-Normark; Robert Whittaker; Lucia Pastore Celentano; Camelia Savulescu
Journal:  Thorax       Date:  2018-10-24       Impact factor: 9.139

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.